Asterias Biotherapeutics Inc (NYSEMKT:AST) COO Katharine E. Spink sold 4,781 shares of the company’s stock in a transaction dated Thursday, October 6th. The shares were sold at an average price of $4.11, for a total transaction of $19,649.91. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Katharine E. Spink also recently made the following trade(s):
- On Friday, September 9th, Katharine E. Spink sold 19,336 shares of Asterias Biotherapeutics stock. The shares were sold at an average price of $3.52, for a total transaction of $68,062.72.
Asterias Biotherapeutics Inc (NYSEMKT:AST) opened at 3.82 on Monday. Asterias Biotherapeutics Inc has a one year low of $2.30 and a one year high of $5.75. The firm’s market cap is $173.50 million. The company has a 50-day moving average of $3.83 and a 200 day moving average of $3.49.
Asterias Biotherapeutics (NYSEMKT:AST) last released its earnings results on Monday, August 15th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The firm earned $1.53 million during the quarter, compared to analyst estimates of $1.14 million. Equities research analysts expect that Asterias Biotherapeutics Inc will post ($0.73) earnings per share for the current fiscal year.
Several equities analysts recently weighed in on the stock. FBR & Co reiterated a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, September 14th. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Asterias Biotherapeutics in a report on Sunday, September 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Asterias Biotherapeutics presently has an average rating of “Buy” and an average target price of $7.75.
A number of institutional investors have recently added to or reduced their stakes in AST. State Street Corp boosted its position in shares of Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares during the last quarter. BlackRock Investment Management LLC boosted its position in shares of Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares during the last quarter. Sabby Management LLC bought a new position in shares of Asterias Biotherapeutics during the second quarter valued at about $741,000. Finally, BlackRock Fund Advisors boosted its position in shares of Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares during the last quarter.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.